The invention relates to a pharmaceutical preparation comprising a radioimmunological conjugate (RIK) for in-vivo elimination of virus-replicating cells in HIV-1, HIV-2, HIV-3, HTLV-1, HTLV-2, HBV, HCV, HDV, CMV, EBV, HHV8 infections and in other chronic virus infections. The radioimmunological conjugate is characterized in that it contains, as immunologically effective constituents; d) a monoclonal antibody or the antigen-binding fragment thereof against a viral or virus-induced antigen expressed on the plasma membrane of virus-infected cells, or; e) a receptor molecule or the fragment thereof with an affinity to an epitope of the viral structural proteins expressed on the plasma membrane of infected cells; or f) a fragment of the cellular receptor molecule, said fragment being modified by mutagenesis, with an affinity to an epitope of the viral structural proteins expressed on the plasma membrane of infected cells. Said conjugate is also characterized in that it contains d) an alpha emitter or a beta emitter as a radioactive constituent. The inventive pharmaceutical preparation also optionally comprises a pharmaceutical carrier and/or adjuvant.
展开▼
